WO2002047661A1 - Pharmaceutical composition for intramuscular injection containing loxoprofen - Google Patents
Pharmaceutical composition for intramuscular injection containing loxoprofen Download PDFInfo
- Publication number
- WO2002047661A1 WO2002047661A1 PCT/KR2001/002161 KR0102161W WO0247661A1 WO 2002047661 A1 WO2002047661 A1 WO 2002047661A1 KR 0102161 W KR0102161 W KR 0102161W WO 0247661 A1 WO0247661 A1 WO 0247661A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- sodium
- loxoprofen
- composition according
- injection
- intramuscular injection
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
Definitions
- the present invention relates to a novel pharmaceutical formulation containing loxoprofen.
- the invention relates to the formulation for intramuscular injection containing loxoprofen or a pharmaceutically acceptable salt thereof, which has an excellent anti-inflammatory analgesic effect, as the active ingredient.
- Loxoprofen (chemical name: 2-[4-(2-oxocyclopentyl)phenyl]propionic acid) is a nonsteroidal anti-inflammatory drug (NSAID) of propionic acid type and is represented by the following formula:
- the above drug is usually used in the form of a sodium salt, that is, as loxoprofen sodium.
- Loxoprofen sodium is effective for the treatment of rheumatoid arthritis, deformant arthritis, lumbo sacral strain, adhesive capsulitis and shoulder-arm-neck syndrome.
- the drug is also known to be effective for relief of post-operative or post- traumatic pains, or for pain relief after tooth extraction. Currently, it is widely used in an oral tablet.
- transdermal formulations thereof such as sustained release adhesive preparations [PCT/JP 1997/02936, Korean Patent Application No 98-41351 (October 1, 1998), US Patent No. 4,740,374 (April 26, 1988), PCT/WO95/ 16440 (June 22, 1995), Korean Patent Application No. 96-38430 (September 5, 1996)].
- Such transdermal formulations have the advantage that they can alleviate side effects or uneasiness from administration of oral formulations for patients having difficulty in oral absorption or requiring a long-term administration.
- the above formulations must also comprise polymers in the same manner as the previously developed adhesive preparations and thus, may cause skin eruptions due to long-term adhesion or skin allergies such as itching, etc. They also cause other side effect such as discomfort in motions of patients. Further, even though the absorption rate of a drug through the skin can be controlled, it takes a long time to obtain the desired therapeutic effect due to difference in the percutaneous absorption rate or absorption amount, depending on a part of pain and physical constitution of each individual. Thus, the transdermal formulations have a drawback that they cannot be used in such emergent cases as suffering from severe pains.
- Loxoprofen sodium has a different reaction mechanism from ketoprofen and ibuprofen, generally known propionic acid-type NSAIDs. It has an excellent anti- inflammatory analgesic effect by the inhibitory action on the biosynthesis of prostaglandin, a causative agent of inflammation and pain. That is, this drug is a pro-drug, which is converted into a trans-OH metabolite, i.e. 2-[para-(trans-2-hydroxycyclopentyl) phenyl]propionic acid in vivo through the metabolism by a ketone reductase upon oral administration.
- a trans-OH metabolite i.e. 2-[para-(trans-2-hydroxycyclopentyl) phenyl]propionic acid in vivo through the metabolism by a ketone reductase upon oral administration.
- the above metabolite exhibits an excellent anti-inflammatory analgesic effect by the inhibitory action on cyclooxygenase, a prostaglandin synthetase [Matsuda et al., Japanese Journal of Inflammation, Vol. 2, No. 3, Summer, pp263-266 (1983)].
- the ketone reductase is mainly distributed in liver or kidney [Tanaka et al., Japanese Journal of Inflammation, Vol. 3, No. 2, Spring, ppl51-155 (1983)].
- the enzyme metabolizes loxoprofen sodium into the trans-OH metabolite to exhibit the strong anti-inflammatory analgesic effect.
- This enzyme is also known to exist on the surface of the skin to exhibit the equivalent pharmacological effect [US Patent No. 4,740,374 (April 26, 1988)].
- oral formulations such as tablets containing loxoprofen or a pharmaceutically acceptable salt thereof as an active ingredient are widely commercialized (Loxonin or Loxfen).
- external formulations such as adhesive preparations and patches have been recently studied. By contrast, no intramuscular injection of this drug has been reported.
- loxoprofen As previously described, it is difficult to administer oral formulations of loxoprofen, which have been developed hitherto, in serious cases with difficulty in the oral absorption or cases with gastroenteric disorders.
- patches under extensive studies have not yet been developed completely.
- the transdermal formulation of loxoprofen must contain many auxiliary agents such as penetration enhancing agents and thus, may cause side effects such as skin eruptions. Moreover, they may cause such discomforts as restricting motions due to the long-term adhesion onto a particular part of the body.
- patches for percutaneous absorption are likely to have many problems in continuously providing the desired pharmacological effects, for example, because they are easily detached from the skin by motions of a joint.
- loxoprofen sodium can provide an excellent anti-inflammatory analgesic effect not only on the skin but also in the muscle through the conversion into the trans-OH metabolite by the ketone reductase.
- the inventors identified that an intramuscular injection of loxoprofen is also applicable to patients having difficulty in the oral absorption.
- the present invention relates to a pharmaceutical composition for intramuscular injection containing loxoprofen of the following formula:
- the pharmaceutically acceptable salt of loxoprofen is loxoprofen sodium.
- loxoprofen or a pharmaceutically acceptable salt thereof is absorbed into the gastrointestinal tract in inactivated forms upon oral administration. Then, it is converted into trans-OH metabolites by action of ketone reductases in the liver or kidney to provide an excellent anti-inflammatory analgesic effect. It is also converted into trans-OH metabolites by action of ketone reductases on the skin to show the same effect.
- the present inventors identified that in the muscle, they are also convertible into trans-OH metabolites by ketone reductases to have the similar effect, particularly, an equivalent or higher effect even in 1/2 to 2/3 of the tablet quantities.
- the present intramuscular injection also provides the fast action satisfying the above requirement.
- the invention provides an intramuscularly injectable formulation of loxoprofen, which can solve side effects of oral formulations such as tablets, e.g. limitation in use for patients having difficulty in the oral absorption or having gastroenteric disorders upon long-term administration.
- the formulation simultaneously solves side effects of formulations for external use, e.g. discomfort in use, skin allergies and the like. Particularly, it can be conveniently used for patients in need of the fast pharmacological effect.
- the formulation of the present invention may be properly prescribed.
- an acidic aqueous solution or a buffer such as a phosphate buffer, which is injectable may be used to adjust its pH thereby to give the injection excellent physical and chemical stability.
- the present formulation may be prepared by dissolving loxoprofen or a pharmaceutically acceptable salt in the water for injection in combination with a stabilizing agent or a solubilizing aid and sterilizing the obtained solution, for example, at a high temperature under vacuum or by aseptic filtration.
- the water for injection may be the distilled water or a buffer, for example, a phosphate buffer or a sodium dihydrogen phosphate (NaH 2 PO 4 )-citric acid buffer having the pH in the range of 3.5 to 7.5.
- the phosphate may be in the form of sodium or potassium salt, or anhydrous or hydrate
- the citric acid may be in the form of anhydrous or hydrate.
- the stabilizing agent which can be used in the present invention, may be sodium pyrosulfite, sodium bisulfite (NaHSO 3 ), sodium metabisulfite or ethylene diamine tetraacetic acid.
- the solubilizing aid may be a base such as sodium hydroxide (NaOH), sodium bicarbonate (NaHCO 3 ), sodium carbonate (Na 2 CO 3 ) and potassium hydroxide
- KOH hydrochloric acid
- HC1 hydrochloric acid
- CH 3 COOH acetic acid
- the formulation of the present invention is preferably a solution having the pH in range of 3.5 to 7.5, or a powder prepared by sterilization and freeze-drying.
- the concentration of the active ingredient is preferably in the range of 2 to 20%.
- Fig. 1 is a comparative distribution curve of the drug plasma concentrations of loxoprofen between tablet and intramuscular injection.
- Loxoprofen sodium and sodium pyrosulfite were dissolved in the distilled water for injection.
- the solution was sterilized at a high temperature under vacuum and filled into a 1 ml ampule to give an intramuscular injection (Table 1).
- Table 1 Composition of the 1 ml intramuscular injection of loxoprofen
- Loxoprofen sodium and sodium pyrosulfite were dissolved in the distilled water for injection. Thereto was added dilute hydrochloric acid to adjust the pH to 6. The resulting solution was sterilized at a high temperature under vacuum, or by aseptic filtration, and filled into a 1 ml ampule to give an intramuscular injection (Table 2).
- Table 2 Composition of the 1 ml intramuscular injection of loxoprofen
- Loxoprofen sodium and sodium pyrosulfite were dissolved in the distilled water for injection. Thereto was added dilute hydrochloric acid to adjust the pH to 5. The resulting solution was sterilized at a high temperature under vacuum, or by aseptic filtration, and filled into a 1 ml ampule to give an intramuscular injection (Table 3).
- Table 3 Composition of the 1 ml intramuscular injection of loxoprofen
- Loxoprofen sodium and sodium metabisulfite were dissolved in the distilled water for injection. Thereto was added dilute hydrochloric acid to adjust the pH to 4. The resulting solution was sterilized at a high temperature under vacuum, or by aseptic filtration, and filled into a 1 ml ampule to give an intramuscular injection (Table 4).
- Table 4 Composition of the 1 ml intramuscular injection of loxoprofen
- Potassium dihydrogen phosphate and sodium hydroxide were dissolved in the distilled water for injection to prepare a phosphate buffer solution of pH 6.5.
- a phosphate buffer solution of pH 6.5 To the prepared buffer solution were dissolved loxoprofen sodium and sodium pyrosulfite. The resulting solution was sterilized at a high temperature under vacuum, or by aseptic filtration, and filled into a 1 ml ampule to give an intramuscular injection (Table 5).
- Table 5 Composition of the 1 ml intramuscular injection of loxoprofen
- Table 7 Composition of the 1 ml intramuscular injection of loxoprofen
- Potassium dihydrogen phosphate and sodium hydroxide were dissolved in the distilled water for injection to prepare a phosphate buffer solution of pH 7.0.
- a phosphate buffer solution of pH 7.0 To the prepared buffer solution were dissolved loxoprofen sodium and sodium pyrosulfite. The resulting solution was sterilized at a high temperature under vacuum, and filled into a 1 ml ampule to give an intramuscular injection (Table 8).
- Table 8 Composition of the 1 ml intramuscular injection of loxoprofen
- Table 9 Composition of the 1 ml intramuscular injection of loxoprofen
- Loxoprofen sodium, sodium pyrosulfite and mannitol were dissolved in the distilled water for injection.
- the solution was sterilized at a high temperature under vacuum, and filled into a 1 ml ampule to give an intramuscular injection (Table 10).
- Table 10 Composition of the 1 ml intramuscular injection of loxoprofen
- Loxoprofen sodium and mannitol were dissolved in the distilled water for injection.
- the solution was aseptically filtered and then, introduced into a vial.
- the vial was freeze- dried to prepare a dry powdered product.
- To the vial was added 1 ml of the distilled water, which was packaged separately from the vial, and stirred to the complete dissolution to give an intramuscular injection (Table 11).
- Table 11 Composition of the 1 ml intramuscular injection of loxoprofen
- Potassium dihydrogen phosphate and sodium hydroxide were dissolved in the distilled water for injection to prepare a phosphate buffer solution of pH 6.5.
- a phosphate buffer solution of pH 6.5 To the prepared buffer solution were completely dissolved mannitol, loxoprofen sodium and sodium pyrosulfite. The resulting solution was aseptically filtered and introduced into a vial. The vial was freeze-dried to prepare a dry powdered product. Before the use, to the vial was added 1 ml of the distilled water, which was packaged separately from the vial, and stirred to the complete dissolution to give an intramuscular injection (Table 12).
- Table 12 Composition of the 1 ml intramuscular injection of loxoprofen
- Loxoprofen and sodium bicarbonate were dissolved in the distilled water to prepare a solution of 1 ml. To this solution was added sodium pyrosulfite and the mixture was stirred to the complete dissolution. The resulting solution was aseptically filtered and introduced into a vial. The vial was freeze-dried to prepare a dry powdered product. Before the use, to the vial was added 1 ml of the distilled water, which was packaged separately from the vial, and stirred to the complete dissolution to give an intramuscular injection (Table 13).
- Table 13 Composition of the 1 ml intramuscular injection of loxoprofen
- Loxoprofen and sodium hydroxide were dissolved in the distilled water to prepare a solution of 1 ml. To this solution was added sodium pyrosulfite and the mixture was stirred to the complete dissolution. The resulting solution was aseptically filtered and introduced into a vial. The vial was freeze-dried to prepare a dry powdered product. Before the use, to the vial was added 1 ml of the distilled water, which was packaged separately from the vial. The mixture was stirred to the complete dissolution to give an intramuscular injection (Table 13).
- Table 14 Composition of the 1 ml intramuscular injection of loxoprofen
- Experiment 1 Comparison of the drug plasma concentrations of loxoprofen between tablet and intramuscular injection in rats The plasma concentration of loxoprofen in the intramuscular injection obtained from Example 1 was evaluated and compared with the commercially available loxoprofen tablet (Loxonin: control) in male SD rats of 6 weeks old free from specific pathogens.
- the formulation was orally administered to the rats with a single dose of 10 mg/kg.
- the formulation was intramuscularly injected to the rats with a single dose of 5 mg/kg.
- the blood gathered from the rats at 2, 5, 10, 20, 30, 60, 120 and 180 minutes after the administration and pretreated. Then, the drug plasma concentrations were analyzed. The following results are the plasma concentration of loxoprofen ( ⁇ g/ml) vs. time (min).
- Table 15 Comparison of the drug plasma concentrations of loxoprofen between tablet and intramuscular injection
- Test material and administration dosage An edema inducing agent, 1% carageenan lambda type IV (Sigma Co.), was subcutaneously injected into the bottom of the paw in the rat to induce the foot edema.
- Loxoprofen sodium was formulated into 5 mg/2 ml and 10 mg/10 ml solutions for an intramuscular injection using phosphate buffer according to the method in Example 5. The obtained formulations were intramuscularly injected with the dose of 5 mg/2 ml/kg, and orally administered with the dose of 10 mg/ml/kg, respectively.
- Test method and calculation formula A standard point was marked in the joint region of the ankle in the left hind paw of the rat and then, the volume of the foot before the administration was measured by plethysmometer (Hugo Sacks & Coulbourn). Test formulations were intramuscularly injected or orally administered to the rats. After 20 minutes, 1% carageenan was subcutaneously injected to the left hind paw of the rats with the dose of 0.1 ml per animal. After 2 hours and 30 minutes, the volume of the foot was measured, and the edema rate and the inhibition rate of edema were calculated by the following formulae:
- Edema rate (%) [(foot edema after injection of the edema inducing agent - foot edema before injection of the edema inducing agent) / foot edema before injection of the edema inducing agent] x 100
- Inhibition rate of edema 100 - [average edema rate of the test material- administered group / average edema rate of the non treatment group 100]
- Table 17 Comparison of foot edemas after the administration of loxoprofen between tablet and intramuscular injection
- Loxoprofen sodium was formulated into solutions of 5 mg/2 ml and 10 mg/10 ml using the phosphate buffer according to the method in Example 5.
- the solutions were intramuscularly injected with a dose of 5 mg/2 ml/kg, and orally administered with a dose of 10 mg/10 ml/kg, respectively.
- a pain inducing agent 0.7% acetic acid in D.W.
- the inhibition rate of pain was 53.7%.
- the inhibition rate of edema was 64.0%. Accordingly, the dominant inhibition rate of pain could be obtained by an intramuscular injection of only 50% dose of the drug compared with an oral administration.
- the intramuscular injection of the present invention can be applied to patients with difficulty in oral absorption, and can also obtain an equivalent or higher anti- inflammatory analgesic effect even in smaller quantities, compared with the oral formulations. Further, it can exhibit the fast action without side effects due to the percutaneous absorption.
Abstract
Description
Claims
Priority Applications (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
BR0108313-9A BR0108313A (en) | 2000-12-14 | 2001-12-13 | Pharmaceutical composition for intramuscular injection containing loxoprofen |
UA2002086717A UA76097C2 (en) | 2000-12-14 | 2001-12-13 | Formulation for intramuscular injection containing loxoprofen |
JP2002549235A JP2004515526A (en) | 2000-12-14 | 2001-12-13 | Loxoprofen-containing pharmaceutical composition for intramuscular injection |
MXPA02007788A MXPA02007788A (en) | 2000-12-14 | 2001-12-13 | Pharmaceutical composition for intramuscular injection containing loxoprofen. |
AU2002222750A AU2002222750A1 (en) | 2000-12-14 | 2001-12-13 | Pharmaceutical composition for intramuscular injection containing loxoprofen |
APAP/P/2002/002594A AP1530A (en) | 2000-12-14 | 2001-12-13 | Pharmaceutical composition for intramuscular injection containing loxoprofen. |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR10-2000-0076298A KR100405161B1 (en) | 2000-12-14 | 2000-12-14 | Pharmaceutical composition for intramuscular injection containing loxoprofen |
KR2000/76298 | 2000-12-14 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2002047661A1 true WO2002047661A1 (en) | 2002-06-20 |
Family
ID=36691545
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/KR2001/002161 WO2002047661A1 (en) | 2000-12-14 | 2001-12-13 | Pharmaceutical composition for intramuscular injection containing loxoprofen |
Country Status (12)
Country | Link |
---|---|
JP (1) | JP2004515526A (en) |
KR (1) | KR100405161B1 (en) |
CN (1) | CN1278672C (en) |
AP (1) | AP1530A (en) |
AR (1) | AR033596A1 (en) |
AU (1) | AU2002222750A1 (en) |
BR (1) | BR0108313A (en) |
MX (1) | MXPA02007788A (en) |
OA (1) | OA12175A (en) |
RU (1) | RU2232572C2 (en) |
UA (1) | UA76097C2 (en) |
WO (1) | WO2002047661A1 (en) |
Cited By (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7547688B2 (en) | 2002-09-13 | 2009-06-16 | Daiichi Sankyo Company, Limited | Methods for treatment of nocturia |
US8227430B2 (en) | 2007-09-04 | 2012-07-24 | Meiji Seika Pharma Co., Ltd | Injectable, injection solution, and injection kit preparation |
JP2012524738A (en) * | 2009-04-22 | 2012-10-18 | フレゼニウス カービ ドイチュラント ゲーエムベーハー | Paracetamol for parenteral administration |
EP2926810A1 (en) | 2014-03-31 | 2015-10-07 | Sanovel Ilac Sanayi ve Ticaret A.S. | Oral liquid pharmaceutical formulations of loxoprofen |
EP2926832A1 (en) | 2014-03-31 | 2015-10-07 | Sanovel Ilac Sanayi ve Ticaret A.S. | Pharmaceutical formulations of loxoprofen for topical use |
EP2939666A1 (en) | 2014-04-29 | 2015-11-04 | Sanovel Ilac Sanayi ve Ticaret A.S. | Pharmaceutical formulations of loxoprofen |
WO2016001133A1 (en) | 2014-06-30 | 2016-01-07 | Sanovel Ilac Sanayi Ve Ticaret A.S. | Loxoprofen and gamma-aminobutiric acid receptor agonist combinations |
WO2016046189A1 (en) | 2014-09-24 | 2016-03-31 | Sanovel Ilac Sanayi Ve Ticaret A.S. | Loxoprofen and antispastic drug combinations |
US9669096B2 (en) | 2003-04-08 | 2017-06-06 | Progenics Pharmaceuticals, Inc. | Stable pharmaceutical formulations of methylnaltrexone |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2011225514A (en) * | 2009-10-30 | 2011-11-10 | Kowa Co | Pharmaceutical composition containing loxoprofen or salt thereof |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4740374A (en) * | 1985-11-26 | 1988-04-26 | Nitto Electric Industrial Co., Ltd. | Anti-inflammatory analgesic adhesive preparation |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH10120560A (en) * | 1996-08-26 | 1998-05-12 | Sankyo Co Ltd | Loxoprofen-containing preparation for external use |
TW577758B (en) * | 1997-10-27 | 2004-03-01 | Ssp Co Ltd | Intra-articular preparation for the treatment of arthropathy |
-
2000
- 2000-12-14 KR KR10-2000-0076298A patent/KR100405161B1/en not_active IP Right Cessation
-
2001
- 2001-12-13 AU AU2002222750A patent/AU2002222750A1/en not_active Abandoned
- 2001-12-13 CN CNB018049494A patent/CN1278672C/en not_active Expired - Fee Related
- 2001-12-13 RU RU2002121772/15A patent/RU2232572C2/en not_active IP Right Cessation
- 2001-12-13 WO PCT/KR2001/002161 patent/WO2002047661A1/en active Application Filing
- 2001-12-13 JP JP2002549235A patent/JP2004515526A/en not_active Withdrawn
- 2001-12-13 MX MXPA02007788A patent/MXPA02007788A/en active IP Right Grant
- 2001-12-13 OA OA1200200244A patent/OA12175A/en unknown
- 2001-12-13 BR BR0108313-9A patent/BR0108313A/en not_active Application Discontinuation
- 2001-12-13 UA UA2002086717A patent/UA76097C2/en unknown
- 2001-12-13 AP APAP/P/2002/002594A patent/AP1530A/en active
- 2001-12-14 AR ARP010105804A patent/AR033596A1/en unknown
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4740374A (en) * | 1985-11-26 | 1988-04-26 | Nitto Electric Industrial Co., Ltd. | Anti-inflammatory analgesic adhesive preparation |
Non-Patent Citations (1)
Title |
---|
SUGEMOTO ET AL.: "Inhibition of prostaglandin production in the inflammatory tissue by loxoprofen-sodium, an anti-inflammatory prodrug", BIOCHEM. PHARMACOL., vol. 42, no. 12, 1991, pages 2363 - 2368 * |
Cited By (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8071763B2 (en) | 2002-09-13 | 2011-12-06 | Daiichi Sankyo Company, Limited | Methods for treatment of nocturia |
US8071649B2 (en) | 2002-09-13 | 2011-12-06 | Daiichi Sankyo Company, Limited | Method for treatment of nocturia |
US7547688B2 (en) | 2002-09-13 | 2009-06-16 | Daiichi Sankyo Company, Limited | Methods for treatment of nocturia |
US9669096B2 (en) | 2003-04-08 | 2017-06-06 | Progenics Pharmaceuticals, Inc. | Stable pharmaceutical formulations of methylnaltrexone |
US10376584B2 (en) | 2003-04-08 | 2019-08-13 | Progenics Pharmaceuticals, Inc. | Stable pharmaceutical formulations of methylnaltrexone |
US8227430B2 (en) | 2007-09-04 | 2012-07-24 | Meiji Seika Pharma Co., Ltd | Injectable, injection solution, and injection kit preparation |
JP2012524738A (en) * | 2009-04-22 | 2012-10-18 | フレゼニウス カービ ドイチュラント ゲーエムベーハー | Paracetamol for parenteral administration |
EP2926832A1 (en) | 2014-03-31 | 2015-10-07 | Sanovel Ilac Sanayi ve Ticaret A.S. | Pharmaceutical formulations of loxoprofen for topical use |
EP2926810A1 (en) | 2014-03-31 | 2015-10-07 | Sanovel Ilac Sanayi ve Ticaret A.S. | Oral liquid pharmaceutical formulations of loxoprofen |
WO2015165847A1 (en) | 2014-04-29 | 2015-11-05 | Sanovel Ilac Sanayi Ve Ticaret A.S. | Pharmaceutical formulations of loxoprofen |
EP2939666A1 (en) | 2014-04-29 | 2015-11-04 | Sanovel Ilac Sanayi ve Ticaret A.S. | Pharmaceutical formulations of loxoprofen |
WO2016001133A1 (en) | 2014-06-30 | 2016-01-07 | Sanovel Ilac Sanayi Ve Ticaret A.S. | Loxoprofen and gamma-aminobutiric acid receptor agonist combinations |
WO2016046189A1 (en) | 2014-09-24 | 2016-03-31 | Sanovel Ilac Sanayi Ve Ticaret A.S. | Loxoprofen and antispastic drug combinations |
Also Published As
Publication number | Publication date |
---|---|
AP2002002594A0 (en) | 2002-09-30 |
KR100405161B1 (en) | 2003-11-12 |
AP1530A (en) | 2006-01-04 |
AR033596A1 (en) | 2003-12-26 |
AU2002222750A1 (en) | 2002-06-24 |
UA76097C2 (en) | 2006-07-17 |
JP2004515526A (en) | 2004-05-27 |
KR20020046407A (en) | 2002-06-21 |
CN1278672C (en) | 2006-10-11 |
OA12175A (en) | 2006-05-09 |
BR0108313A (en) | 2003-03-11 |
CN1400892A (en) | 2003-03-05 |
RU2232572C2 (en) | 2004-07-20 |
MXPA02007788A (en) | 2002-10-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US6291527B1 (en) | Pharmaceutical preparations containing hydrosoluble ketoprofen salts and their application | |
EP1439830B1 (en) | Pharmaceutical composition of 2-(4-isobutylphenyl) propionic acid | |
HUP0101246A2 (en) | Novel galenic formulations of meloxicam for oral administration and process for their preparation | |
SK284092B6 (en) | Pharmaceutical composition of flurbiprofen for treating sore throat and use thereof | |
WO2008144730A3 (en) | Stable pharmaceutical formulation for a dpp-iv inhibitor | |
US6727286B2 (en) | Pharmaceutical composition of 2-(4-isobutylphenyl) propionic acid | |
AU2002224475A1 (en) | Pharmaceutical composition of 2-(4-isobutylphenyl) propionic acid | |
WO2002047661A1 (en) | Pharmaceutical composition for intramuscular injection containing loxoprofen | |
EP2074990B1 (en) | Controlled release flurbiprofen and muscle relaxant combinations | |
JP2021520400A (en) | Edaravone pharmaceutical composition | |
RU2528897C2 (en) | Formulation for oral transmucosal use of lipid-lowering agents | |
JP4854158B2 (en) | Formulations containing benzamide derivatives as active ingredients | |
JP2008143856A (en) | Pharmaceutical compounded with nonsteroidal anti-inflammatory agent | |
JP4864369B2 (en) | Method for stabilizing thiamines | |
WO2004050110A1 (en) | Medicinal composition | |
JP2011046666A (en) | Medicinal composition | |
TWI301413B (en) | Pharmaceutical composition for intramuscular injection containing loxoprofen | |
JP2010280609A (en) | Treating agent of internal bleeding by stiffness in shoulder, lower back pain, muscular pain, bruise, sprain, cervicobrachial syndrome, and external injury | |
JPS6216929B2 (en) | ||
CA2103666C (en) | Products containing verapamil and trandolapril | |
JPH0696527B2 (en) | Anti-inflammatory analgesic gel | |
AU600715B2 (en) | Method of lowering uric acid blood levels in humans | |
IE56574B1 (en) | Pharmaceutical formulations | |
IE900512L (en) | Pentamidine solutions | |
RU2345775C1 (en) | Nonsteroid antiinflammatory medicinal agent |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 1200200724 Country of ref document: VN |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1-2002-500025 Country of ref document: PH |
|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PH PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
WWE | Wipo information: entry into national phase |
Ref document number: PA/a/2002/007788 Country of ref document: MX |
|
WWE | Wipo information: entry into national phase |
Ref document number: 018049494 Country of ref document: CN |
|
ENP | Entry into the national phase |
Ref document number: 20020564 Country of ref document: UZ Kind code of ref document: A Ref document number: 2002 549235 Country of ref document: JP Kind code of ref document: A |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
122 | Ep: pct application non-entry in european phase |